A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Conditions

• Migraine

Eligibility Criteria

Sex

ALL

Age

12 Years - 17 Years

Healthy Volunteers

Not accepted

Interventions

• Rimegepant — DRUG
  Rimegepant 75 mg orally disintegrating tablets
• Placebo — DRUG
  Matching placebo oral disintegrating tablets

Study Details

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day. Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months. In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period. Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at all visits. Participants will have to complete a daily diary to record the migraine attacks.

Key Dates

Start date

Nov 15, 2024

Status verified

Jun 2026

Primary completion

Oct 8, 2026

Completion

Dec 2, 2027

Study Design

Enrollment

200 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Rimegepant
  Experimental medicine under study
• Placebo Comparator: Placebo
  A placebo does not have any medicine in it but looks just like the medicine being studied.

Primary Outcome Measure

Number of migraine days per month [ Time Frame: 12 Weeks ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (27)

Find similar trials in Phoenix, AZ

Related Studies

• Quality Improvement and Practice Based Research in Neurology Using the EMR
  PHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
• Pain Biomarker Study
  PHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
• Mind Body Balance for Pediatric Migraine
  Recruiting · Children's Hospital Medical Center, Cincinnati · Aurora, Colorado
• Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
  PHASE2 · Recruiting · Stanford University · Stanford, California